Alison Betts

2.1k total citations
31 papers, 1.4k citations indexed

About

Alison Betts is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Alison Betts has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Radiology, Nuclear Medicine and Imaging, 20 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Alison Betts's work include Monoclonal and Polyclonal Antibodies Research (22 papers), HER2/EGFR in Cancer Research (13 papers) and CAR-T cell therapy research (6 papers). Alison Betts is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (22 papers), HER2/EGFR in Cancer Research (13 papers) and CAR-T cell therapy research (6 papers). Alison Betts collaborates with scholars based in United States, United Kingdom and Netherlands. Alison Betts's co-authors include Dhaval K. Shah, Nahor Haddish‐Berhane, Piet H. van der Graaf, K. Dane Wittrup, Tracey Clark, Katie F. Maass, Puja Sapra, Lindsay B. Avery, Hannah M. Jones and Lindsay E. King and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Journal of Pharmaceutical Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

Alison Betts

31 papers receiving 1.3k citations

Peers

Countries citing papers authored by Alison Betts

Since Specialization

Citations

This map shows the geographic impact of Alison Betts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Betts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Betts more than expected).

Fields of papers citing papers by Alison Betts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Betts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Betts. The network helps show where Alison Betts may publish in the future.

Co-authorship network of co-authors of Alison Betts

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Betts. A scholar is included among the top collaborators of Alison Betts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Betts. Alison Betts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), Nirav N. Shah, Martin Lechmann, Hardik Mody, Marc W. Retter, Min Zhu, Tommy Li, Jun Wang, M. Naveed Shaik, (unknown), Meric Ovacik, Fei Hua, Vibha Jawa, Christophe Boetsch, Yanguang Cao, John M. Burke, (unknown), Kapil Gadkar, Vijay Upreti, Alison Betts	2
2	Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs) 2023 ·Journal of Pharmacokinetics and Pharmacodynamics ·(unknown), Khem Raj Ghusinga, (unknown), Maksymilian Nowak, (unknown), Joshua F. Apgar, (unknown), Alison Betts	15
3	Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1 2020 ·Journal of Pharmacokinetics and Pharmacodynamics ·Alison Betts, Tracey Clark, Paul Jasper, John Tolsma, Piet H. van der Graaf, Edmund I. Graziani, Edward Rosfjord, Matthew Sung, Dangshe Ma, Frank Barletta	19
4	A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART® 2019 ·The AAPS Journal ·Alison Betts, Nahor Haddish‐Berhane, Dhaval K. Shah, Piet H. van der Graaf, Frank Barletta, Lindsay King, Tracey Clark, Cris Kamperschroer, Adam Root, Andrea T. Hooper, Xiaoying Chen	54
5	Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach 2018 ·Journal of Pharmacokinetics and Pharmacodynamics ·Dhaval K. Shah, Frank Loganzo, Nahor Haddish‐Berhane, Sylvia Musto, (unknown), Frank Barletta, Judy Lucas, Tracey Clark, (unknown), Alison Betts	17
6	A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin 2016 ·DSpace@MIT (Massachusetts Institute of Technology) ·(unknown), Alison Betts, Katie F. Maass, Mohiuddin Quadir, Paula T. Hammond, K. Dane Wittrup	3
7	Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design 2016 ·The AAPS Journal ·Katie F. Maass, (unknown), Alison Betts, K. Dane Wittrup	60
8	Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin 2016 ·The AAPS Journal ·Alison Betts, Nahor Haddish‐Berhane, John Tolsma, Paul Jasper, Lindsay E. King, Yongliang Sun, Chakrapani Subramanyam, Boris Shor, Joseph Boni, Theodore R. Johnson	48
9	A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin 2015 ·Journal of Pharmaceutical Sciences ·Katie F. Maass, (unknown), Mohiuddin Quadir, Paula T. Hammond, Alison Betts, K. Dane Wittrup	11
10	A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate 2014 ·The AAPS Journal ·Dhaval K. Shah, Lindsay E. King, Xiaogang Han, (unknown), Yanhua Zhang, Judy Lucas, Nahor Haddish‐Berhane, Alison Betts, Mauricio Leal	45
11	Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition 2014 ·The AAPS Journal ·Aman P. Singh, Wojciech Krzyżański, Steven W. Martin, Gregory L. Weber, Alison Betts, Alaa Ahmad, Anson K. Abraham, Anup Zutshi, (unknown), (unknown)	40
12	Antibody biodistribution coefficients 2013 ·mAbs ·Dhaval K. Shah, Alison Betts	178
13	On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach 2013 ·Journal of Pharmacokinetics and Pharmacodynamics ·Nahor Haddish‐Berhane, Dhaval K. Shah, Dangshe Ma, Mauricio Leal, Hans‐Peter Gerber, Puja Sapra, Hugh A. Barton, Alison Betts	55
14	Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates 2013 ·Expert Review of Clinical Pharmacology ·Puja Sapra, Alison Betts, Joseph Boni	21
15	Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin 2012 ·Journal of Pharmacokinetics and Pharmacodynamics ·Dhaval K. Shah, Nahor Haddish‐Berhane, Alison Betts	118
16	Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human 2011 ·Journal of Pharmacokinetics and Pharmacodynamics ·Dhaval K. Shah, Alison Betts	323
17	The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis 2010 ·Journal of Pharmacology and Experimental Therapeutics ·Alison Betts, Tracey Clark, Jianxin Yang, Judith L. Treadway, Mei Li, (unknown), Yasmina Abdiche, Donna M. Stone, Vishwas Paralkar	77
18	Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human 2010 ·Xenobiotica ·(unknown), Alison Betts, David Hepworth, Anne C. Heatherington	7
19	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists 2009 ·Bioorganic & Medicinal Chemistry Letters ·Simon J. Mantell, Karl R. Gibson, Simon A. Osborne, Graham N. Maw, H. Rees, (unknown), (unknown), Gareth W. Harbottle, (unknown), (unknown), Steven England, (unknown), Alison Betts, (unknown), (unknown)	12
20	Impact of Physicochemical and Structural Properties on the Pharmacokinetics of a Series of α1L-Adrenoceptor Antagonists 2007 ·Drug Metabolism and Disposition ·Alison Betts, (unknown), Iain Gardner, David A. Fox, Rob Webster, Kevin Beaumont, Paul Morgan	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact